Grant: Catalyst Grant: Analysis of CLSA Data - IA Early Career Researchers
McGill University
$70,000.00
Epigenetic age acceleration and overall mortality among cancer survivors
FY 2024-25
Summary
Aging is a biological process that increases our vulnerability to chronic health conditions. As we age, our bodies undergo various biological changes that can affect our health. One way to measure the effects of aging on our bodies is through epigenetic changes, specifically DNA methylation. DNA methylation can alter gene expression without changing the underlying genetic code. This process plays a significant role in regulating various biological functions, and disruptions in methylation patterns have been linked to several chronic diseases including cardiovascular, neurodegenerative diseases, and cancer. Epigenetic clocks are tools that help estimate biological age based on DNA methylation patterns. By comparing biological age to chronological age, we reveal a difference known as epigenetic age acceleration. EAA may indicate how our bodies age and how that aging relates to chronic diseases. EAA serves as a marker of accelerated aging, indicating how quickly an individual is aging biologically compared to their chronological age. Individuals with higher EAA may have an increased risk of developing age-related diseases. Additionally, these patients often exhibit signs of accelerated biological aging, which can be linked to poorer treatment outcomes and survival rates. Despite existing epigenetic clocks, there are limitations in their ability to predict disease risk and outcomes accurately. This project aims to address these limitations by validating a deep learning model to estimate epigenetic age using data from the Canadian Longitudinal Study on Aging (CLSA). We will use data from CLSA to evaluate EAA and assess how effectively it can differentiate between individuals with and without chronic diseases. Additionally, we will explore how EAA correlates with survival rates among these patients. Insights gained from this research could lead to the development of more personalized approaches to chronic disease care, ultimately enhancing patient outcomes.
Department
Program
Catalyst Grant: Analysis of CLSA Data - IA Early Career Researchers
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
521883
Name
Madathil Sreenath A
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Aging
Theme2
Social / Cultural / Environmental / Population Health
Prcname2
Catalyst Grant: Analysis of CLSA Data
Projecttitle
Epigenetic age acceleration and overall mortality among cancer survivors
Programtype2
Operating Grants
Orgnameinp2
McGill University
Cihramount2
$70,000
Cihrequipment2
$0
Programname2
Catalyst Grant: Analysis of CLSA Data - IA Early Career Researchers
Keyworddelim
Artificial Intelligence; Chronic Diseases; Epigenetic Age Acceleartion; Mortality
Abstract
Aging is a biological process that increases our vulnerability to chronic health conditions. As we age, our bodies undergo various biological changes that can affect our health. One way to measure the effects of aging on our bodies is through epigenetic changes, specifically DNA methylation. DNA methylation can alter gene expression without changing the underlying genetic code. This process plays a significant role in regulating various biological functions, and disruptions in methylation patterns have been linked to several chronic diseases including cardiovascular, neurodegenerative diseases, and cancer. Epigenetic clocks are tools that help estimate biological age based on DNA methylation patterns. By comparing biological age to chronological age, we reveal a difference known as epigenetic age acceleration. EAA may indicate how our bodies age and how that aging relates to chronic diseases. EAA serves as a marker of accelerated aging, indicating how quickly an individual is aging biologically compared to their chronological age. Individuals with higher EAA may have an increased risk of developing age-related diseases. Additionally, these patients often exhibit signs of accelerated biological aging, which can be linked to poorer treatment outcomes and survival rates. Despite existing epigenetic clocks, there are limitations in their ability to predict disease risk and outcomes accurately. This project aims to address these limitations by validating a deep learning model to estimate epigenetic age using data from the Canadian Longitudinal Study on Aging (CLSA). We will use data from CLSA to evaluate EAA and assess how effectively it can differentiate between individuals with and without chronic diseases. Additionally, we will explore how EAA correlates with survival rates among these patients. Insights gained from this research could lead to the development of more personalized approaches to chronic disease care, ultimately enhancing patient outcomes.
Competitiondate
202410
Approvedterm2
1 yr 0 mth
Pinamesdelim
Madathil, Sreenath A; Nicolau, Belinda F
Approvedterm
1 an 0 mois
Cihrcontribution2
IA~ $70,000~ $0~